Pharmacists may earn 1.00 CPE Credit (0.10 CEU) by completing this course on the American Society of Health-System Pharmacists (ASHP) website. Please click here to go to the course (you will leave the myCME website, and free registration on the ASHP website is required). Your certificate will save on ASHP.org and will not be included in your myCME CME History.
This continuing medical education activity is provided by the American Society of Health-System Pharmacists (ASHP).
Supported by an educational grant from Merck.
Morbidity and mortality associated with invasive fungal infections remain high despite the availability of novel antifungals and new therapeutic strategies. This activity will review the emergence of invasive fungal infections in immunocompromised patients. New diagnostic tests and techniques for diagnosing patients with invasive fungal infections will be reviewed as will current treatments for aspergillosis and mucormycosis in immunocompromised patients. The activity will conclude by examining the challenges healthcare providers in the community confront in the diagnosis and treatment of invasive fungal infections in immunocompromised patients.
This activity was planned to meet the educational needs of physicians, pharmacists, nurse practitioners, and physician assistants caring for patients at risk for invasive fungal infections.
At the conclusion of this knowledge-based educational activity, participants should be able to:
Review the emerging epidemiology of invasive fungal infections in immunocompromised patients.
Review new diagnostic tests and techniques for diagnosing invasive fungal infections.
Discuss current treatments for immunocompromised patients with suspected or confirmed aspergillosis or mucormycosis taking into account pharmacokinetic and pharmacodynamic parameters.
Examine challenges faced by healthcare providers in the community in diagnosing and treating immunocompromised patients with invasive fungal infections, including interprofessional strategies for overcoming them.
Conflict Of Interest Disclosure Policy
In accordance with ACCME and ACPE Standards for Commercial Support, ASHP policy requires that all faculty, planners, reviewers, staff, and others in a position to control the content of this presentation disclose their financial relationships.
Peggy L. Carver, PharmD, FCCP, FIDP Associate Professor of Pharmacy University of Michigan College of Pharmacy Clinical Pharmacist, Infectious Diseases Michigan Medicine Ann Arbor, Michigan
Dr. Chandrasekar discloses the following: Speakers bureau: Astellas
Accredited Provider Disclosure
The planners and managers reported no financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity.
AMA PRA Category 1 Credit(s)TM
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Society of Health-System Pharmacists designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditsTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This activity may contain references to unlabeled uses of U.S. Food and Drug Administration (FDA)-approved products or to products not approved by FDA. Faculty will inform participants of any such references.
In order to receive credit, participants must complete the pre-assessment questions, post-assessment questions, and program evaluation. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.
For information about the accreditation of this program, please contact firstname.lastname@example.org.